{"id":"W2132365366","doi":"10.1158/1078-0432.ccr-09-2944","title":"Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":96,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Tolerability; Lung cancer; Regimen; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Pharmacokinetics; Oncology; Pharmacology; Gastroenterology; Phases of clinical research; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008572496,0.0002241098,0.0004930208,0.0001470956,0.00009896089,0.00004825043,0.0003627538,0.0002195429,0.00006926907],"category_scores_gemma":[0.00009438558,0.000165313,0.00006000072,0.0004828608,0.000255747,0.00001023254,0.0003334848,0.000310624,8.866584e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006113822,"about_ca_system_score_gemma":0.000543453,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006635386,"about_ca_topic_score_gemma":0.0173089,"domain_scores_codex":[0.99763,0.0002793572,0.0005505782,0.000776362,0.0003115397,0.0004521717],"domain_scores_gemma":[0.9984987,0.0001017132,0.0001677815,0.0004906376,0.0005112849,0.0002298477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004853616,0.02014085,0.8824349,0.00005381288,0.0001961715,0.00001965141,0.0002410909,0.000002415651,0.05571605,7.457099e-7,0.001548669,0.03479204],"study_design_scores_gemma":[0.2589072,0.1096351,0.2939261,0.0003580004,0.0004217646,0.00000238987,0.001133791,0.0006406779,0.3220916,0.000006489976,0.01170757,0.001169269],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944774,0.002680753,0.000002941443,0.00004104535,0.0001850236,0.002244134,0.0001507745,0.000004402343,0.0002135219],"genre_scores_gemma":[0.9952633,0.002311893,0.00007715425,0.00003823719,0.0002071185,0.0009794107,0.00004389942,0.00004132073,0.001037611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5885088,"threshold_uncertainty_score":0.9999795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09942401494546313,"score_gpt":0.4720793940494459,"score_spread":0.3726553791039827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}